Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $4.78 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aditxt Inc. had its IPO on 2020-06-30 under the ticker symbol ADTX.
The company operates in the Healthcare sector and Biotechnology industry. Aditxt Inc. has a staff strength of 58 employees.
Shares of Aditxt Inc. opened at $0.83 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $0.83 - $0.89, and closed at $0.85.
This is a -3.72% slip from the previous day's closing price.
A total volume of 19,400 shares were traded at the close of the day’s session.
In the last one week, shares of Aditxt Inc. have slipped by -13.74%.
Aditxt Inc.'s Key Ratios
Aditxt Inc. has a market cap of $4.78 million, indicating a price to book ratio of 0.5245 and a price to sales ratio of 7.9501.
In the last 12-months Aditxt Inc.’s revenue was $853153 with a gross profit of $27055 and an EBITDA of $-26374260. The EBITDA ratio measures Aditxt Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aditxt Inc.’s operating margin was -3138.22% while its return on assets stood at -86.33% with a return of equity of -339.11%.
In Q3, Aditxt Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aditxt Inc.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-66.43 per share while it has a forward price to earnings multiple of 0.3707 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aditxt Inc.’s profitability.
Aditxt Inc. stock is trading at a EV to sales ratio of 1.1427 and a EV to EBITDA ratio of -0.0239. Its price to sales ratio in the trailing 12-months stood at 7.9501.
Aditxt Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $19.18 million
- Total Liabilities
- $4.37 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aditxt Inc. ended 2023 with $19.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.18 million while shareholder equity stood at $12.69 million.
Aditxt Inc. ended 2023 with $0 in deferred long-term liabilities, $4.37 million in other current liabilities, 3731.00 in common stock, $-86828138.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.24 million and cash and short-term investments were $9.24 million. The company’s total short-term debt was $1,449,592 while long-term debt stood at $0.
Aditxt Inc.’s total current assets stands at $12.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.25 million compared to accounts payable of $2.71 million and inventory worth $1.44 million.
In 2023, Aditxt Inc.'s operating cash flow was $87438.00 while its capital expenditure stood at $4183.
Comparatively, Aditxt Inc. paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aditxt Inc. stock is currently trading at $0.85 per share. It touched a 52-week high of $28.49 and a 52-week low of $28.49. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.23 and 200-day moving average was $4.24 The short ratio stood at 0.43 indicating a short percent outstanding of 0%.
Around 116.1% of the company’s stock are held by insiders while 1594.9% are held by institutions.
Frequently Asked Questions About Aditxt Inc.
Similar Industry Stocks (Biotechnology)
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.